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Staphylococcus aureusThe characterization of heteroresistant vancomycin-intermediate Staphylococcus aureus strains (hVISA) is
even more challenging, as no routine standardized laboratory methods are available. A total of 124 S. aureus
isolates recovered from inpatients attended in hospitals of Santa Catarina State, Southern Brazil, were
evaluated. The MIC of vancomycin, teicoplanin, and daptomycin was determined by Etest and prediffusion
tests using NeoSensitabs® tablets. All isolates were susceptible to vancomycin (MICs: 0.5–3 μg/mL) by Etest.
However, according to prediffusion test, 17 isolates presented reduced susceptibility to vancomycin, and of
these, 12 were conﬁrmed as hVISA using populational analysis. Considering daptomycin, prediffusion results
were in agreement with susceptibility data (MICs), as all isolates were susceptible. Considering that
characterizing hVISA is challenging and that MIC determination is not adequate to characterize this
phenotype, prediffusion test was a viable alternative to screening hVISA and reduced susceptibility to
vancomycin. It was simple and low cost, with accuracy comparable to other well-established methods.rtment, University Regional of
cosilveira@furb.br© 2014 Elsevier Inc. All rights reserved.1. Introduction
Vancomycin is a glycopeptide known since 1955, when it was
placed at the disposal of medicine through the work of McCormick
(McCormick et al., 1955). Initially, due to the success of methicillin,
oxacillin, and other isoxazolepenicillins, it was not often used, though
with the emergence of methicillin resistance in the 1960's, it came to
be used quite often. In 1996, a strain of Staphylococcus aureus
intermediate to vancomycin (vancomycin-resistant S. aureus [VISA])
was identiﬁed in Japan (Hiramatsu, 1997). This phenotype did not
have a wide dissemination, and the drugmost frequently used to treat
infections caused by methicillin-resistant S. aureus (MRSA) is still
vancomycin, as well as the daptomycin and linezolid (Jones, 2006;
Van Hal and Fowler, 2013).
Detection of in vitro susceptibility of isolates to these drugs is
challenging. Since 2009, the CLSI (2013) no longer recommends disk
diffusion to determine vancomycin susceptibility due to its high
molecular weight resulting in decreased diffusion in culture media
(Heather et al., 2010). Based on current CLSI recommendations,
susceptibility to linezolid and teicoplaninmay be determined by diskdiffusion method, while vancomycin and daptomycin susceptibili-
ties should be assessed by dilution methods or some speciﬁc
diffusion tests in agar. These tests are extremely laborious and
expensive, making them difﬁcult to implement, especially in
developing countries.
Taking into account the seriousness of MRSA infections, early and
aggressive antimicrobial therapy is an important part to reduce
mortality. Treatment failures in infections caused by susceptible
isolates are primarily due to heteroresistant vancomycin-intermediate
S. aureus strains (hVISA), a subpopulationwith reduced susceptibility to
vancomycin. Thus, in vitro susceptibility may not be enough for the
physician to achieve treatment success. The evaluation of tolerance
to glycopeptide antibiotics is important for predicting treatment
failure (Van Hal and Paterson, 2011) and can be considered the ﬁrst
step to preventing and controlling the emergence of vancomycin
resistance in S. aureus (Howden et al., 2010). As the hVISA
resistance phenotype manifests itself heterogeneously and is a
minor component of the bacterial population (1 in 106 microor-
ganisms), the methods commonly used in clinical microbiology
laboratories (MIC determination by Etest or microdilution) fail to
detect potential resistance, and vancomycin therapy may fail
(Satola et al., 2011).
NeoSensitabs® (Rosco Diagnostica, Taastrup, Denmark) are tablets
containing antimicrobial (9 mm diameter and 1.5 mm thick) stable at
room temperature, which were developed to evaluate bacterial
Fig. 1. Scattergram with distribution of vancomycin prediffusion results compared to
MICs. Horizontal lines represent the CLSI breakpoints for susceptibility (b4 μg/mL) and
resistance (N8 μg/mL); vertical line represents the breakpoint for a prediffusion-
positive result (susceptible N22 mm).
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teicoplanin, daptomycin, and colistin. The initial prediffusion allows a
homogeneous diffusion of the antibiotic in the culture medium, making
possible to discriminate strains with reduced susceptibility to these
agents. The aim of this study was to evaluate the prediffusion
methodology for the detection of decreased susceptibility to glycopep-
tides and daptomycin as well as its use in the detection of hVISA isolates.
2. Methods
2.1. Samples
Clinical isolates (n = 124) were collected (March 2009 to
February 2013) from inpatients in three hospitals in Florianópolis
(Hospital de Caridade, Hospital Governador Celso Ramos, and
Cardio SOS) and a hospital in Blumenau (Hospital Santa Isabel), all
located in Santa Catarina state, Southern Brazil. One isolate per
patient was considered. All isolates were used, and there was no
selection bias. Identiﬁcation was done using the following testes:
Gram staining, catalase production, mannitol fermentation, coag-
ulase, and DNase production. Susceptibility to methicillin was
determined by cefoxitin disk diffusion, according to the interpre-
tive criteria of CLSI (M100-S23).
2.2. Phenotypic tests for screening and conﬁrmation of hVISA
Three screening tests were used for the detection of hVISA strains.
BHI agar plates containing 4 μg/mL of vancomycin and 16 g/L of
pancreatic digest of casein were inoculated with a prepared 0.5
McFarland standard inoculum. After 24 h of incubation at 35–37 °C,
the growth of more than 20 colonies was considered a positive test for
hVISA (Satola et al., 2011). Using Etest® Glycopeptide Resistance
Detection (GRD) (bioMerieux, Durham, NC, USA), the isolate was
considered hVISAwhen theMIC for teicoplanin is 12 μg/mL or 8 μg/mL
for teicoplanin and vancomycin after 48 h (Van Hal et al., 2011). The
Etest® macromethod (bioMerieux) was performed using a 2.0
McFarland inoculum on BHI agar plates and readings taken at 24
and 48 h, where an MIC of 8 μg/mL to vancomycin identiﬁed hVISA
isolates (Van Hal et al., 2011).
All isolates with at least 1 positive screening test were conﬁrmed
through population analysis proﬁle/area under the curve (PAP-AUC).
The area under the curve (AUC) was calculated using Mu3 (hVISA) as a
control strain. For conﬁrmation of an hVISA isolate, the ratio of AUC for
the isolate divided by that of Mu3 should be greater than or equal to 0.9
and non-hVISA isolates had a PAP-AUC b0.9 (Wootton et al., 2001).
2.3. Minimum inhibitory concentration (MIC)
MIC values to vancomycin, teicoplanin, and daptomycin were
obtained by the Etest® methodology (bioMerieux). Interpretation
was performed, following CLSI (M100-S23) guideline.
2.4. Prediffusion tests
Neosensitabs® containing 30 μg vancomycin, 30 μg teicoplanin, or
30 μg daptomycin/100 μg calcium (Rosco Diagnostica) and prediffu-
sion tests were performed following the manufacturer's guidelines
(Supplement User's Guide, 2010). The tablets were placed on the
surface of Mueller Hinton agar (bioMerieux). They were inverted and
incubated for 2 h at room temperature. After this period, plates were
incubated for further 18–22 h at room temperature to ensure the
complete diffusion of antibiotics. Then, plates were inoculated with
bacteria and incubated at 35 °C for 24 h and inhibition evaluated.
Isolates with vancomycin ≤22 mm and/or teicoplanin b20 mm
inhibition zones were considered VISA/hVISA. For daptomycin,
isolates b2 mm were deﬁned as resistant.2.5. Quality control
To ensure the quality and accuracy of the test results, S. aureus
strains ATCC 29213 (MSSA), ATCC 43300 (MRSA), ATCC 700698
(hVISA), and ATCC 700699 (VISA) were used.3. Results
All isolates were susceptible to vancomycin, considering E-test
results. MICs were 0.5 μg/mL (0.8%), 0.75 μg/mL (0.8%), 1.0 μg/mL
(17.7%), 1.5 μg/mL (42.7%), 2.0 μg/mL (32.3%), and 3.0 μg/mL (5.6%)
(Fig. 1). The isolates that had an MIC of 3 μg/mL were considered
susceptible to vancomycin since all had MIC obtained by broth
macrodilution values ≤2 μg/mL. Considering these data, all isolates
would be characterized according to CLSI criteria as susceptible to
vancomycin. Seventeen isolates had discrepant results for MIC and
prediffusion: they were considered susceptible by the CLSI break-
points. Among the 17 discrepant isolates, 2 had an MIC of 1.5 μg/mL,
10 presented MIC of 2.0 μg/mL, and 5 MIC of 3.0 μg/mL.
Teicoplanin data indicated MICs of 0.19 μg/mL (0.8%), 0.25 μg/mL
(0.8%), 0.38 μg/mL (1.6%), 0.5 μg/mL (3.2), 0.75 μg/mL (1.6%), 1.0 μg/mL
(4.8%), 1.5 μg/mL (17.7%), 2.0 μg/mL (16.9%), 3.0 μg/mL (33.9%),
4.0 μg/mL (13.7%), 6.0 μg/mL (1.6%), 8.0 μg/mL (2.4%), and 12.0 μg/mL
(0.8%) (Fig. 2). Discrepancies were observed for 14 isolates, whichwere
classiﬁed as intermediate according to prediffusion testing but
considered susceptible according to CLSI criteria. Among them, 1 had
an MIC of 1.5 μg/mL, 7 at 3.0 μg/mL, 4 at 4.0 μg/mL, and 2 at 8.0 μg/mL.
Vancomycin and teicoplanin susceptibility data demonstrated that
21 clinical isolates were intermediately susceptible to vancomycin
and/or teicoplanin, which indicated these isolates were VISA using the
prediffusion method.
All isolates were submitted to screening tests for the hVISA
phenotype (GRD, Etest® macromethod, and agar screening with
vancomycin), and of those that tested positive for any of the 3
screening tests, the phenotype was conﬁrmed by PAP-AUC. Of the 124
isolates, 12 (9.7%) were characterized as hVISA (Table 1).
Based on the above data, 91.7% sensitivity, 83.1% speciﬁcity, a
positive predictive value of 52.4%, a negative predictive value of 97.1%,
and an accuracy of 89.5% were established for prediffusion test
(Table 2).
Daptomycin data indicated MIC values of 0.125 μg/mL (3.2%), 0.19
μg/mL (5.6%), 0.25 μg/mL (8.9%), 0.38 μg/mL (23.4%), 0.5 μg/mL
(33.9%), 0.75 μg/mL (21%), and 1.0 μg/mL (4%) (Fig. 3). All isolates
presented, therefore, a susceptible phenotype.
Prediffusion results for ATCC700698 (hVISA) and ATCC 700699
(VISA) are demonstrated in Fig. 4, as well as the results of 2 clinical
isolates (SI11 and L10).
Fig. 2. Scattergramwith the distribution of teicoplanin prediffusion results compared to
MICs. Vertical line represents the breakpoint for a prediffusion-positive result
(susceptible N19 mm).
Fig. 3. Scattergram with the distribution of daptomycin prediffusion results compared
to MICs. All isolates were susceptible.
Table 1
Comparison of PAP results (hVISA and non-hVISA) with prediffusion results.
hVISA Non-hVISA Total
Positive prediffusion 11 10 21
Negative prediffusion 1 102 103
Total 12 112 124
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The prediffusion method is an alternative to conventional
methods, allowing antimicrobials with high molecular weight to be
evaluated by this alternative disk diffusion, since by conventional
methodology, they do not have cutoffs in CLSI guidelines.
Surprisingly, few studies have been published using prediffusion
for the assessment of S. aureus susceptibility to glycopeptides and
daptomycin (Katz et al., 2008; Nielsen and Casals, 2005). The major
disadvantage of prediffusion considering glycopeptide susceptibility
is that the methodology is unable to differentiate between hVISA and
VISA isolates. Besides, it is a qualitative methodology without the
possibility to determine MICs. Its qualitative data have presented a
good correlation with MIC results, suggesting this test may be used as
an alternative test.
In this study, prediffusion data for daptomycin were also highly
consistent with MIC results, which were also observed by other
authors (Katz et al., 2008). Altogether, these data may support the
clinical use of prediffusion test. However, more data must be
generated to conﬁrm this hypothesis.
Since 2009, CLSI no longer recommends disk diffusion methodol-
ogy for vancomycin, requiring clinical laboratories to determine theTable 2
Results showed that a disagreement between the prediffusion and screening tests for hVISA.
Isolate Vancomycin (mm) Teicoplanin (mm) Etest GRD vancomycin/teicoplanin (μg/mL) Agar screening Etest macromethod (μg/mL) PAP-AUC Interpretation
SI1 21 21 1.5/4 No 8 0.8 False positive
SI5 22 18 2/6 No 8 0.77 False positive
SI9 22 19 1/1.5 No 6 0.72 False positive
SI10 21 17 1.5/6 No 8 0.86 False positive
SI12 21 16 2/8 Yes 12 0.89 False positive
SI26 22 18 1.5/8 Yes 6 0.78 False positive
SI29 21 19 3/8 Yes 8 0.84 False positive
L4 25 18 1.5/2 Yes 4 0.63 False positive
L10 23 20 2/8 Yes 4 0.92 False negative
L64 21 20 1.5/4 No 8 0.79 False positive
L83 24 19 1/4 No 3 0.71 False positiveMIC. Despite being a microdilution reference test, MIC testing is
somehow laborious and requires validation. Therefore, several
laboratories use the Etest® as an alternative methodology to
determine MIC, which is more expensive and tends to overestimate
the MIC (Van Hal et al., 2011). However, it is practical and shows a
strong correlation with clinical results, justifying its wide usage.
A meta-analysis published in 2012 correlated vancomycin MIC
values determined by Etest®with therapeutic failure. The study found
a signiﬁcant correlation between isolates having an MIC ≥ 1.5 μg/mL
and therapeutic failure, with an odds ratio of 1.74 (95% conﬁdence
interval: 1.34–2.21; P b 0.01) (Van Hal et al., 2012). Thus, we used the
MICs determined by Etest, in an attempt to ﬁnd a correlation between
the results of prediffusion and Etest.
Several phenotypic tests have been used to detect hVISA as the
heteroresistant phenotype has no reliable molecular characterization
marker(s) and required the use of phenotypic tests with varying
sensitivities and speciﬁcities. Satola et al. (2011) reported that
screening on BHI agar with 4 μg/mL of vancomycin presents 91%
sensitivity and 94% speciﬁcity rates, while the Etest® macromethod
shows a sensitivity of 57% and speciﬁcity of 96% and Etest ® GRD
shows a sensitivity of 57% and speciﬁcity of 97%.
This study has some limitations. First, the methodology used to
determine the MIC was the Etest®, even though the gold standard is
the broth microdilution. Second, all isolates tested were susceptible to
daptomycin, making it necessary to evaluate the performance of the
prediffusion-resistant isolates to determine if the method may
present good accuracy for this antimicrobial agent.
These data indicated that when comparing the prediffusion
method used for detecting hVISA, the speciﬁcity (83.1%) and
sensitivity (91.7%) rates from this study were similar to other widely
used tests. The results demonstrated that, despite being infrequently
used, this test could be viable and effective in screening clinical
isolates for an hVISA phenotype. The high negative predictive value
(97.1%) allows for testing negative, excluding the possibility of that
Fig. 4. The pictures above illustrate prediffusion, highlighting the control strains: (A) Mu50 ATCC 700699 (VISA), (B) Mu3 ATCC 700698 (hVISA), and 2 clinical isolates, (C) SI11 and
(D) L10, both having the hVISA phenotype. V = vancomycin; T = teicoplanin; D = daptomycin.
404 A.C.O. Silveira et al. / Diagnostic Microbiology and Infectious Disease 79 (2014) 401–404the phenotype. Taking into account that all positive screening tests
should be conﬁrmed with PAP-AUC, the prediffusion method, as a
simple and low-cost test, should be considered not only as a useful
test to assess the susceptibility of S. aureus to glycopeptides and
daptomycin, but also as a screening test for hVISA.
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